Who really invented CRISPR? If it was many people and labs, who did it first and who deserves the credit? When things like Nobel Prizes and Patents get decided on CRISPR-Cas9, who will be for lack of a better way of putting it, the winners and the losers? It’s not a trivial question and despite what some argue that CRISPR shouldn’t be patented at all, someone will get the decisive patent and the fight to see who prevails in the CRISPR patent battle is getting …Read More
The patent dispute on CRISPR between UC/Jennifer Doudna and The Broad/Feng Zhang has been the subject of major attention including in a recent piece on Stanford Center for Law & Biosciences Blog. There is a lot of confusion over this important CRISPR dispute so I turned to a patent expert for their take on this via an interview below. The interview with this anonymous expert provides some helpful, informed assessments on the CRISPR patent dispute including fresh perspectives. This person has different views than those expressed in …Read More
A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically, it seems like the first CRISPR IPO could get the lion’s share of investor money, but then there’s the patent thing hanging over all of this (see below) Patent …Read More
With more than 250 votes cast, Jennifer Doudna is leading by a decisive margin in a poll asking who deserves the patent for use of CRISPR-Cas9 as a tool. Feng Zhang got only just over half the votes of Doudna. Another take home message from this poll is that a sizable minority–almost one in five– said neither should have a patent on this technology. Geographically the results were fairly consistent across countries, but notably in the UK the top response was, “Neither”. This poll is …Read More
There is no hotter technology than CRISPR-Cas9 gene editing tools. Perhaps it is not surprising then that there is a patent dispute over it, which falls into two camps: (1) Jennifer Doudna & Emmanuelle Charpentier, and (2) Feng Zhang. Who deserves the intellectual property for use of CRISPR-Cas9 in human cells? Take our poll.